Literature DB >> 2114801

Age and human immunodeficiency virus infection in persons with hemophilia in California.

R C Holman1, E D Gomperts, J M Jason, C F Abildgaard, M T Zelasky, B L Evatt.   

Abstract

Thirteen hemophilia centers provide comprehensive care to approximately 90 percent of persons with hemophilia in California. For 1987, these centers reported patient human immunodeficiency virus (HIV) antibody status, age group, level of clotting factor deficiency, and hemophilia type on 1,438 persons with hemophilia A and B; HIV serologic status was known for 860 persons (59.8 percent) of whom 537 (62.4 percent) were HIV-antibody-positive. The HIV positivity rate increased with age after taking into account hemophilia type, clotting factor level and treatment center type. The three-year cumulative incidence of reported AIDS (acquired immunodeficiency syndrome) cases based on the number of HIV positive patients, was 11.6 percent. The cumulative incidence rate was 14.6 percent (54 of 370) for those patients over 20 years of age and 4.8 percent (8 of 167) for those under 21 years of age. Although a comparable distribution of the date of diagnoses of AIDS was seen by age group, there appeared to be a bimodal distribution in the rate of AIDS among the age groups, with the 6-12-year-olds and the 21 and older age groups showing higher incidence rates.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2114801      PMCID: PMC1404766          DOI: 10.2105/ajph.80.8.967

Source DB:  PubMed          Journal:  Am J Public Health        ISSN: 0090-0036            Impact factor:   9.308


  9 in total

1.  Coincidental appearance of LAV/HTLV-III antibodies in hemophiliacs and the onset of the AIDS epidemic.

Authors:  B L Evatt; E D Gomperts; J S McDougal; R B Ramsey
Journal:  N Engl J Med       Date:  1985-02-21       Impact factor: 91.245

2.  AIDS incubation period in male haemophiliacs.

Authors:  M J Turner; J O White; W P Soutter
Journal:  Nature       Date:  1987 Dec 24-31       Impact factor: 49.962

3.  AIDS incubation period.

Authors:  H Ekert
Journal:  Nature       Date:  1987 Oct 8-14       Impact factor: 49.962

4.  A prospective study of human immunodeficiency virus type 1 infection and the development of AIDS in subjects with hemophilia.

Authors:  J J Goedert; C M Kessler; L M Aledort; R J Biggar; W A Andes; G C White; J E Drummond; K Vaidya; D L Mann; M E Eyster
Journal:  N Engl J Med       Date:  1989-10-26       Impact factor: 91.245

5.  Development and early natural history of HTLV-III antibodies in persons with hemophilia.

Authors:  M E Eyster; J J Goedert; M G Sarngadharan; S H Weiss; R C Gallo; W A Blattner
Journal:  JAMA       Date:  1985-04-19       Impact factor: 56.272

6.  Three-year incidence of AIDS in five cohorts of HTLV-III-infected risk group members.

Authors:  J J Goedert; R J Biggar; S H Weiss; M E Eyster; M Melbye; S Wilson; H M Ginzburg; R J Grossman; R A DiGioia; W C Sanchez
Journal:  Science       Date:  1986-02-28       Impact factor: 47.728

7.  Natural history of human immunodeficiency virus infections in hemophiliacs: effects of T-cell subsets, platelet counts, and age.

Authors:  M E Eyster; M H Gail; J O Ballard; H Al-Mondhiry; J J Goedert
Journal:  Ann Intern Med       Date:  1987-07       Impact factor: 25.391

Review 8.  HLA haplotype A1 B8 DR3 as a risk factor for HIV-related disease.

Authors:  C M Steel; C A Ludlam; D Beatson; J F Peutherer; R J Cuthbert; P Simmonds; H Morrison; M Jones
Journal:  Lancet       Date:  1988-05-28       Impact factor: 79.321

9.  Hemophilia-associated AIDS in the United States, 1981 to September 1987.

Authors:  J K Stehr-Green; R C Holman; J M Jason; B L Evatt
Journal:  Am J Public Health       Date:  1988-04       Impact factor: 9.308

  9 in total
  2 in total

Review 1.  Infectious disease issues in xenotransplantation.

Authors:  R S Boneva; T M Folks; L E Chapman
Journal:  Clin Microbiol Rev       Date:  2001-01       Impact factor: 26.132

2.  Heterosexual and mother-to-child transmission of AIDS in the hemophilia community.

Authors:  T L Chorba; R C Holman; B L Evatt
Journal:  Public Health Rep       Date:  1993 Jan-Feb       Impact factor: 2.792

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.